GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (OTCPK:NONOF) » Definitions » Cyclically Adjusted Revenue per Share

Novo Nordisk A/S (Novo Nordisk A/S) Cyclically Adjusted Revenue per Share : $4.51 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Novo Nordisk A/S Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Novo Nordisk A/S's adjusted revenue per share for the three months ended in Dec. 2023 was $2.154. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $4.51 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Novo Nordisk A/S's average Cyclically Adjusted Revenue Growth Rate was 12.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 14.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 12.60% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 12.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Novo Nordisk A/S was 14.50% per year. The lowest was 6.30% per year. And the median was 11.50% per year.

As of today (2024-04-28), Novo Nordisk A/S's current stock price is $124.64. Novo Nordisk A/S's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $4.51. Novo Nordisk A/S's Cyclically Adjusted PS Ratio of today is 27.64.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Novo Nordisk A/S was 29.45. The lowest was 8.17. And the median was 11.69.


Novo Nordisk A/S Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Novo Nordisk A/S's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Cyclically Adjusted Revenue per Share Chart

Novo Nordisk A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.81 3.44 3.46 3.96 4.51

Novo Nordisk A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.96 4.10 4.24 4.23 4.51

Competitive Comparison of Novo Nordisk A/S's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Novo Nordisk A/S's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk A/S's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's Cyclically Adjusted PS Ratio falls into.



Novo Nordisk A/S Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novo Nordisk A/S's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=2.154/116.7000*116.7000
=2.154

Current CPI (Dec. 2023) = 116.7000.

Novo Nordisk A/S Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.710 99.600 0.832
201406 0.747 99.700 0.874
201409 0.735 99.700 0.860
201412 0.782 99.400 0.918
201503 0.702 100.200 0.818
201506 0.788 100.300 0.917
201509 0.784 100.200 0.913
201512 0.827 99.800 0.967
201603 0.797 100.200 0.928
201606 0.816 100.600 0.947
201609 0.819 100.200 0.954
201612 0.833 100.300 0.969
201703 0.818 101.200 0.943
201706 0.881 101.200 1.016
201709 0.863 101.800 0.989
201712 0.904 101.300 1.041
201803 0.913 101.700 1.048
201806 0.884 102.300 1.008
201809 0.897 102.400 1.022
201812 0.942 102.100 1.077
201903 0.927 102.900 1.051
201906 0.953 102.900 1.081
201909 0.941 102.900 1.067
201912 1.020 102.900 1.157
202003 1.063 103.300 1.201
202006 0.966 103.200 1.092
202009 1.049 103.500 1.183
202012 1.130 103.400 1.275
202103 1.168 104.300 1.307
202106 1.160 105.000 1.289
202109 1.227 105.800 1.353
202112 1.270 106.600 1.390
202203 1.363 109.900 1.447
202206 1.288 113.600 1.323
202209 1.336 116.400 1.339
202212 1.514 115.900 1.524
202303 1.701 117.300 1.692
202306 1.755 116.400 1.760
202309 1.872 117.400 1.861
202312 2.154 116.700 2.154

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Novo Nordisk A/S  (OTCPK:NONOF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Novo Nordisk A/S's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=124.64/4.51
=27.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Novo Nordisk A/S was 29.45. The lowest was 8.17. And the median was 11.69.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Novo Nordisk A/S Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Industry
Address
Novo Alle 1, Bagsvaerd, DNK, DK-2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.